Thermophile peptidoglycan hydrolase fusion proteins and uses thereof
The disclosure relates to chimeric recombinant lysins comprising at least one thermophile endolysin catalytic domain and at least one cell wall binding domain. Also disclosed are polynucleotides encoding the chimeric recombinant lysins, host cells expressing the chimeric recombinant lysins, and use of such chimeric recombinant lysins.
1. A polynucleotide encoding a chimeric recombinant lysin, comprising:
[I] a first nucleic acid molecule encoding at least one thermophile endolysin catalytic domain from:
[i] PlyGspY412 as set forth in SEQ ID NO: 4, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 4;
[ii] PlyGspY4 as set forth in SEQ ID NO: 16, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 16; or
[iii] PlyGve2 as set forth in SEQ ID NO: 23, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 23;
[II] a second nucleic acid molecule encoding at least one cell wall binding domain from C. perfringens endolysins:
[a] PlyCP10 as set forth in SEQ ID NO: 5, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 5;
[b] PlyCP18 as set forth in SEQ ID NO: 6, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 6;
[c] PlyCP33 as set forth in SEQ ID NO: 7, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 7;
[d] PlyCP41 as set forth in SEQ ID NO: 8, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 8; or
[e] PlyCP26 as set forth in SEQ ID NO: 9, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 9;
[III] optionally a third nucleic acid molecule encoding a linker between the thermophile endolysin catalytic domain and the cell wall binding domain; and
[IV] optionally a fourth nucleic acid molecule encoding a polyhistidine tag, wherein the chimeric recombinant lysin is not a fusion of PlyGve2 and PlyCP26.
2. The polynucleotide of claim 1 , wherein the thermophile endolysin catalytic domain is from PlyGspY412 and the cell wall binding domain is from C. perfringens endolysins PlyCP10, PlyCP18, PlyCP33, PlyCP41, or PlyCP26.
3. The polynucleotide of claim 1 , wherein the thermophile endolysin catalytic domain is from PlyGspY4 and the cell wall binding domain is from C. perfringens endolysins PlyCP10, PlyCP18, PlyCP33, PlyCP41, or PlyCP26.
4. The polynucleotide of claim 1 , wherein the thermophile endolysin catalytic domain is from PlyGVE2 and the cell wall binding domain is selected from C. perfringens endolysins PlyCP10, PlyCP18, PlyCP33, PlyCP41, and PlyCP26; and wherein the chimeric recombinant lysin does not have an amino acid sequence of SEQ ID NO: 28.
5. The polynucleotide of claim 1 , wherein the chimeric recombinant lysin comprises a polynucleotide encoding a polyhistidine tag with an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
6. The polynucleotide of claim 1 , wherein:
the thermophile endolysin catalytic domain has the amino acid sequence of SEQ ID NO: 4; SEQ ID NO: 16; or SEQ ID N: 23;
the cell wall binding domain has the amino acid sequence of SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; or SEQ ID NO: 9; and wherein the chimeric recombinant lysin does not have an amino acid sequence as set forth in SEQ ID NO: 28.
7. The polynucleotide of claim 1 , wherein the chimeric recombinant lysin has an amino acid sequence selected from the group consisting of SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; and SEQ ID NO: 27.
8. A nucleic acid construct comprising the polynucleotide of claim 1 operably linked to a promoter.
9. A vector comprising the polynucleotide of claim 1 .
10. A host cell comprising the polynucleotide of claim 1 .
11. The host cell of claim 10 , wherein the host cell is selected from the group consisting of a bacterial cell, a fungal cell, a plant cell, and a mammalian cell.
12. A chimeric recombinant lysin polypeptide comprising:
[I] at least one thermophile endolysin catalytic domain from:
[i] PlyGspY412 as set forth in SEQ ID NO: 4, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 4;
[ii] PlyGspY4 as set forth in SEQ ID NO: 16, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 16; or
[iii] PlyGve2 as set forth in SEQ ID NO: 23, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 23;
[II] at least one cell wall binding domain from C. perfringens endolysins:
[a] PlyCP10 as set forth in SEQ ID NO: 5, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 5;
[b] PlyCP18 as set forth in SEQ ID NO: 6, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 6;
[c] PlyCP33 as set forth in SEQ ID NO: 7, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 7;
[d] PlyCP41 as set forth in SEQ ID NO: 8, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 8; or
[e] PlyCP26 as set forth in SEQ ID NO: 9, or a variant thereof having at least 90% sequence identity to SEQ ID NO: 9;
[III] optionally a third nucleic acid molecule encoding a linker between the thermophile endolysin catalytic domain and the cell wall binding domain; and
[IV] optionally a fourth nucleic acid molecule encoding a polyhistidine tag,
wherein the chimeric recombinant lysin polypeptide is not a fusion of PlyGve2 and PlyCP26.
13. The chimeric recombinant lysin polypeptide of claim 12 , wherein the thermophile endolysin catalytic domain is from PlyGspY412 and the cell wall binding domain is from C. perfringens endolysins PlyCP10, PlyCP18, PlyCP33, PlyCP41, or PlyCP26.
14. The chimeric recombinant lysin polypeptide of claim 12 , wherein the thermophile endolysin catalytic domain is from PlyGspY4, and the cell wall binding domain is from C. perfringens endolysins PlyCP10, PlyCP18, PlyCP33, PlyCP41, or PlyCP26.
15. The chimeric recombinant lysin polypeptide of claim 12 , wherein the thermophile endolysin catalytic domain is from PlyGVE2 and the cell wall binding domain is selected from from C. perfringens endolysins PlyCP10, PlyCP18, PlyCP33, PlyCP41, or PlyCP26; and
wherein the chimeric recombinant lysin does not have an amino acid sequence of SEQ ID NO: 28.
16. The chimeric recombinant lysin polypeptide of claim 12 , wherein the polypeptide comprises a polyhistidine tag.
17. The chimeric recombinant lysin polypeptide of claim 12 , wherein:
the amino acid sequence of the thermophile endolysin catalytic domain is SEQ ID NO: 4; SEQ ID NO: 16; or SEQ ID N: 23;
the amino acid sequence of the cell wall binding domain is SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; or SEQ ID NO: 9; and
wherein the chimeric recombinant lysin does not have an amino acid sequence of SEQ ID NO: 28.
18. The chimeric recombinant lysin polypeptide of claim 17 , wherein the polypeptide has an amino acid sequence of SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; or SEQ ID NO: 27.
19. A host cell comprising the polypeptide of claim 12 .
20. The host cell of claim 19 , wherein the host cell is selected from a bacterial cell, a fungal cell, a plant cell, and a mammalian cell.
21. A composition comprising the chimeric recombinant lysin polypeptide of claim 12 , and optionally a pharmaceutically acceptable carrier.
22. The composition of claim 21 , comprising a pharmaceutically acceptable carrier.
23. The composition of claim 21 , wherein the composition is formulated for oral administration.
24. The composition of claim 23 , where the composition is animal feed.
25. A method of treating infection and disease caused by C. perfringens in an individual in need thereof, comprising administering to said individual an effective dose of the composition of claim 23 .
26. The method of claim 25 , wherein the infection is necrotic enteritis.
27. The method of claim 25 , wherein the individual is a chicken, a pig, or newborn calf.
28. The method of claim 25 , wherein the infection is gas gangrene.
29. A method of preparing a chimeric recombinant lysin polypeptide, comprising cultivating the host cell of claim 10 in a suitable medium, under conditions that allow expression of the polypeptide, preparing the polypeptide, and optionally further comprising recovering the polypeptide.
30. A method of treating infection and disease caused by C. perfringens in an individual in need thereof, comprising administering to said individual the host cell of claim 11 .